#cardiac biomarkers market share

[medicaldevicesindustrynews]

Increasing Demand for Cardiac Biomarkers Due to Growing Prevalence of Heart Attacks

Increasing Demand for Cardiac Biomarkers Due to Growing Prevalence of Heart Attacks

During heart damage, or distress, several components are released into the blood, which is further measured to help in diagnosing cardiac ischemia, acute coronary syndrome, and conditions affecting the heart palpitation, such as insufficiency of blood flow to the heart. Such components or substances are known as cardiac biomarkers. These are tested to help in diagnosing the cardiac disease risk…

[bhushans]

A Market on the Move: Exploring Investment Opportunities in Global Radiopharmaceutical Market

The global  radiopharmaceutical market is poised for substantial growth, driven by significant healthcare expenditures and scientific innovations in affluent economies. According to a recent report by Future Market Insights (FMI), the market is expected to achieve a valuation of USD 6972.1 million by 2024.

Increasing awareness of the benefits of radioisotope medications is a key factor propelling this growth. The market is projected to expand at a compound annual growth rate (CAGR) of 3.40% from 2024 to 2034, with an estimated market value surpassing USD 11635 million by the end of the forecast period.

Request Your Detailed Report Sample With Your Work Email: https://www.futuremarketinsights.com/reports/sample/rep-gb-1992

However, the market may be constrained by the half-life of radiopharmaceuticals. It’s common knowledge that radiopharmaceuticals require larger financial outlays. Radiation pharmaceuticals’ short half-life or expectation is one of the main issues limiting demand. As a result, only developed areas may currently use radiopharmaceuticals more and more. The developing economies still have a way to go before fully utilizing technology. In its most recent industry analysis, named “Radiopharmaceuticals Market,” Future Market Insights has gone over these features with potential future developments.

Key Takeaways from Radiopharmaceuticals Market

North America dominates the radiopharmaceuticals market due to rising frequency of cardiovascular diseases and cancer and the scenario is expected to persist even in the forecast period. Adopting innovative radioisotope production methods for treating chronic disorders is another reason.

Europe, led by the UK, is also expected to hold a significant market share due to the UK being subject to maximum incidences of cancer. Cancer Research UK estimate says that the UK alone houses 367,167 cancer patients.

The Asia-Pacific is poised to grow blatantly in the forecast period with it witnessing new product launches, collaborations, distribution agreements, acquisitions in an aplomb.

“The fact that radiopharmaceuticals are broadly used as biomarkers in molecular imaging is expected to take the radiopharmaceuticals market by storm in the upcoming period”, says an analyst from Future Market Insights.

Competitive Landscape

GE Healthcare inked an agreement with NorthStar Medical Radioisotopes, LLC for producing and distributing iodine-123 (I-123) capsules all across the US.

Bracco Diagnostics Inc., in March 2021, entered into partnership with CardioNavix, LLC for enhancing patients’ access to cardiac PET imaging. The new program is termed as ‘Bracco Mobile Isotope Service’, which ought to facilitate better patient care sites for providing cardiac PET imaging.

Jubilant Radiopharma, in August 2020, signed a MoU (Memorandum of Understanding) with Navidea Biopharmaceuticals, which focuses on an ELDA (Exclusive License and Distribution Agreement) for the latter’s diagnostic imaging agent called ‘Tilmanocept (technetium Tc 99m tilmanocept injection) in LATAM, Mexico, Canada, and the US.

Bayer AG, in June 2021, announced that it would acquire Noria Therapeutics Inc. along with PSMA Therapeutics Inc. with the objective of widening the former’s oncology portfolio that is into existence.

Norgine B.V., in March 2020, completed the acquisition of Azanta A/S, a specialty biopharmaceutical company. This included Nimorazole, a hypoxic radiosensitizer to treat cancer, and Angusta to facilitate labor induction.

Curium, in the year 2019, completed acquisition of MAP Medical, which would actually help it in strengthening the footprint all over the Europe with access to Baltic and Nordic countries.

The US FDA, in December 2020, completed approval of Gallium 68 PSMA-11 (Ga 68 PSMA-11). It holds the distinction of being the very first drug for PET imaging for diagnosing prostate cancer.

Key Companies Profiled:

Siemens AG

Positron Corporation

Novartis (Advanced Accelerator Applications)

Curium

GE Healthcare

Lantheus Holdings Inc.

Sotera Health LLC (Nordion Inc.)

Bayer AG

Eckert & Ziegler

Key Segments Covered in the Radiopharmaceuticals Industry Analysis:

Radiopharmaceuticals Market by Radioisotope Type:

Technetium-99

Fluorine-18

Iodine-131

Leutetium-177

Yttrium-90

Gallium-68

Gallium-67

Rubidium-82

Iodine-123

Iodine-125

Indium-111

Others

Radiopharmaceuticals Market by Application:

Oncology

Cardiology

Gastroenterology

Neuroendocrinology

Neurology

Nephrology

Others

Radiopharmaceuticals Market by Source:

Cyclotrons

Nuclear Reactors

Radiopharmaceuticals Market by End User:

Hospitals

Diagnostic Imaging Centers

Ambulatory Surgical Centers

Cancer Research Institute

Radiopharmaceuticals Market by Region:

North America Radiopharmaceuticals Market

Latin America Radiopharmaceuticals Market

Western Europe Radiopharmaceuticals Market

Eastern Europe Radiopharmaceuticals Market

APEJ Radiopharmaceuticals Market

Japan Radiopharmaceuticals Market

Middle East & Africa Radiopharmaceuticals Market

[priteshwemarketresearch]

Glaucoma Market Size, Share, Trends Analysis Report 2033

The report presents an in-depth assessment of the ‘Glaucoma Market’. This includes enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, competitive analysis, operator case studies, opportunities, future trends, value chains, ecosystem player profiles, and strategies included. The report also presents a SWOT analysis and forecast for Glaucoma investments from 2024 to 2033.

Click the link to get a sample copy of the report: https://wemarketresearch.com/reports/request-free-sample-pdf/glaucoma-market/1443

Top Companies in the Glaucoma Market:

Ziemer Ophthalmic Systems Topco

Lumenis

Novartis

Santen Pharmaceutical

New World Medical

Johnson & Johnson

Allergan

Ellex Medical Lasers

Abbott Laboratories

Others 

Global Glaucoma Market Segments:

 By Drug Class

Beta Blockers

Prostaglandin Analog

Adrenergic Agonist

Carbonic Anhydrase Inhibitors

Others

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Regional Analysis for Glaucoma Market

For a comprehensive understanding of market dynamics, the global Glaucoma market is analysed across key geographies namely North America, Europe, China, Japan, Southeast Asia, India, Central & South America. Each of these regions is analyzed based on market research findings for the key countries in the region for a macro-level understanding of the market.

Important sections of the TOC

Economic Impact Variables on Glaucoma Market: Illuminates the consequences of environmental, political and economic fluctuations, and explains changes in customer and consumer requirements. We also provide a detailed report of Glaucoma on the technology risks and advancements in the global market.

Forecasts based on macro- and micro-economy: ensuring price, revenue and volume EV charging service forecasts for the market. It also includes, in addition to forecasting growth, revenue and import volume for the region, with revenue forecasting for the Glaucoma application, along with revenue forecasting by cost, revenue and type.

Marketing Strategy Analysis: In this section, Glaucoma analysis aims at niche positioning and provides information regarding target audience, new strategies and pricing strategies. We provide a comprehensive Glaucoma marketing station analysis that investigates the problem. Marketing channel development trends, direct marketing as well as indirect marketing.

Business Intelligence: The Glaucoma companies studied in this section are also assessed by key business, gross margin, price, sales, revenue, product category, applications and specifications, Glaucoma competitors, and manufacturing base.

Directly Buy a Copy of this Glaucoma Market research report at@https://wemarketresearch.com/purchase/glaucoma-market/1443?license=single

Why to buy this Report?

The report provides valuable insights into market trends, growth opportunities, and competitive landscapes. By reading a technology report, businesses and investors can gain a better understanding of the market they are operating in or considering entering, and make more informed decisions based on data and analysis.

The report reports provide detailed information on competitors' strengths, weaknesses, and strategies, which can help businesses identify potential threats and opportunities in the market.

The report provides insights into emerging technologies and trends, which can help businesses stay up-to-date with the latest developments and make informed decisions about where to invest their resources.

The report can be used by investors and acquirers as part of their due diligence process when considering investing in or acquiring a technology company. These reports can provide valuable information on the company's financials, technology, market position, and other key factors.

Related Reports

Cardiac Biomarker Market

Solar PV Combiner Box Market

Carbon Steel Market

Additive Manufacturing Market

About We Market Research:

WE MARKET RESEARCH is an established market analytics and research firm with a domain experience sprawling across different industries. We have been working on multi-county market studies right from our inception. Over the time, from our existence, we have gained laurels for our deep rooted market studies and insightful analysis of different markets.

Our strategic market analysis and capability to comprehend deep cultural, conceptual and social aspects of various tangled markets has helped us make a mark for ourselves in the industry. WE MARKET RESEARCH is a frontrunner in helping numerous companies; both regional and international to successfully achieve their business goals based on our in-depth market analysis. Moreover, we are also capable of devising market strategies that ensure guaranteed customer bases for our clients.

Contact Us:

Mr. Robbin Joseph

Corporate Sales, USA

We Market Research

USA: +1-724-618-3925

Websites: https://wemarketresearch.com/

Email: sales@wemarketresearch.com

[omkarpatel]

Surface Plasmon Resonance is Estimated to Witness High Growth Owing to Opportunity to Develop Biosensor Applications

Surface Plasmon Resonance (SPR) is a powerful optical technique for characterizing biomolecular interactions. It enables the label-free detection and analysis of biomolecular interactions in real-time, providing important information about kinetics, affinity and concentration of interactions. SPR has wide applications in detecting or measuring proteins, dna, virus and biomarkers. It is commonly used to determine epitope mapping, antibody screening, protein complex formation, agglutination analysis, and receptor-ligand interactions. SPR applications have grown beyond basic bio-interaction analysis and SPR biosensors have emerged in medical diagnostics, food safety testing, and environmental monitoring. The global Surface Plasmon Resonance Market is estimated to be valued at US$ 976.1 Mn in 2023 and is expected to exhibit a CAGR of 6.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: The opportunity to develop biosensor applications of Surface Plasmon Resonance technology is driving the market growth. SPR biosensors have potential applications in detecting disease biomarkers in real time with high sensitivity. Research is ongoing to use SPR for developing portable biosensors to detect pathogens, toxins and proteins related to cancer, cardiac or infectious diseases directly from biological samples. SPR based biosensors could enable point-of-care testing without the need for specialized technicians or laboratory settings. This will increase accessibility of diagnostics. Development of cost-effective SPR biosensors has potential to disrupt the healthcare diagnostics market. Porter's Analysis Threat of new entrants: The threat of new entrants is moderate as surface plasmon resonance instruments require high upfront capital investments and expertise to operate. Research and development in this field is also costly. Bargaining power of buyers: The bargaining power of buyers is moderate to high as there are many established suppliers in the market providing similar products. Buyers can negotiate for better price and quality. Bargaining power of suppliers: The bargaining power of suppliers is moderate as they depends on few automated instrumentation and consumable parts suppliers. Supplier switching cost is moderate. Threat of new substitutes: Threat of new substitutes is low as SPR technique has well established itself in the market and no major substitute technology provides its advantages. Competitive rivalry: The competition in the market is high among major players to increase their revenue share. SWOT Analysis Strength: SPR offers direct, real-time detection of biomolecular interactions without labelling. It has high sensitivity and reproducibility. Weakness: High instrumentation and consumable costs. Require skilled personnel for operation and data analysis. Opportunity: Growing proteomics, metabolomics and biomarker research will boost demand. Increasing R&D investments in pharmaceutical industries offer opportunities. Threats: Slow adoption in developing countries due to budget constraints. Competition from emerging label-free detection technologies. Key Takeaways The global surface plasmon resonance market is expected to witness high growth supported by ongoing protein-protein interaction and clinical biomarker studies. North America dominates the market currently owing to extensive R&D activities in the region. The market in Asia Pacific is expected to witness fastest growth over the forecast period with increasing government investments in life science research in countries like China and India. Key players operating in the surface plasmon resonance market includes Bio-Rad Laboratories, Inc., Carterra Inc., AMETEK, Inc., Bristol Myers Squibb, Horiba, Ltd., Bruker, and Biosensing Instrument Inc. Major players are focusing on new product launches with advanced features and geographical expansion strategies to gain higher revenue shares in the global market.

[sophiareddy123]

The Cardiac Biomarkers Market is segmented by Type (Creatine Kinase, Troponins, Myoglobin, Ischemia Modified Albumin, and Other Types), Application (Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, and Other Applications) Location of Testing (Point-of-care Testing and Laboratory Testing), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). 

Download Free Sample Report - Cardiac Biomarkers Market

[snehahealthcareblogs]

Digital Biomarkers Market : To Exhibits Remarkable Growth | $14.7 Billions by 2032

Digital biomarkers market was a rapidly emerging and evolving sector within healthcare and life sciences. Digital biomarkers are quantifiable and objective physiological and behavioral data collected and measured through the use of digital devices and technologies. These data can provide valuable insights into an individual's health status and can be used for various purposes, including disease diagnosis, monitoring, and treatment optimization.

Request Sample Report: https://www.alliedmarketresearch.com/request-sample/132906

Here are some key points about the digital biomarkers market:

Growing Importance: The digital biomarkers market was gaining importance due to advancements in wearable technology, mobile health apps, and remote monitoring tools. These technologies allowed for the continuous collection of health-related data, enabling healthcare providers to monitor patients more effectively.

Applications: Digital biomarkers found applications in various healthcare domains, including cardiology, neurology, psychiatry, and oncology. For example, in cardiology, wearable devices could track heart rate, activity levels, and sleep patterns to assess cardiac health.

Clinical Trials: Pharmaceutical companies were increasingly using digital biomarkers in clinical trials to collect real-world data on the efficacy and safety of drugs. Digital biomarkers helped streamline the drug development process and reduce costs.

Data Privacy and Security: The collection and use of personal health data through digital biomarkers raised concerns about data privacy and security. Regulations such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States and the General Data Protection Regulation (GDPR) in Europe played a crucial role in addressing these concerns.

Market Players: Several technology companies, healthcare organizations, and startups were entering the digital biomarkers market. This included companies producing wearable devices, developing health apps, and creating data analytics platforms to make sense of the collected data.

Challenges: Challenges in the digital biomarkers market included standardization of data collection and analysis methods, regulatory hurdles, and the need for interoperability among various devices and systems.

By application, the digital biomarkers market size is classified into cardiovascular disease, sleep and movement disease, neurological disorders, and others (respiratory diseases, diabetes, psychiatric and musculoskeletal disorders). The cardiovascular disease segment is projected to be the fastest growing segment during the forecast period owing to rise in prevalence of cardiovascular diseases and high in number of product provision of digital biomarkers for cardiovascular disease monitoring and diagnosis.

By clinical practice, the digital biomarkers market share is classified into monitoring, diagnostic and prognostic. The monitoring segment is projected to be the fastest growing segment during the forecast period owing to rise in adoption of digital biomarkers for monitoring purpose and hogh presence of manufacturers who manufactures digital biomarkers for monitoring.

By end user, the digital biomarkers market analysis is classified into healthcare companies, hospitals, and others (payers and patients). The healthcare companies segment is projected to be the fastest growing segment during the forecast period owing to rise in number of clinical trials and research activities using digital biomarkers by healthcare companies.

[aartichede08]

Analysis Of Lateral Flow Assay Market From 2019 To 2028

Lateral flow assays are simple and reliable antibody-based assays, providing a rapid method for the detection of specific biomarkers above a detection threshold.  Lateral flow assays offer a fast, simple, and low-cost option for precision diagnostics. In the field of on-site diagnostics, lateral flow assay (LFA) are settled commercial product because of their capacity of giving exact, quick, and low-cost result. Lateral flow assay technology is quickly advanced throughout the years and routinely utilized for purpose of point-of-care and companion diagnostic applications. In addition, technological advances to transform the assays from simple qualitative tests into complex multi-analyte quantitative assay are driving development of the lateral flow assay market.  Applications of lateral flow assay include tests on pathogens, drugs, hormones and metabolites in biomedical, veterinary, feed/food and environmental settings 

To know the scope of our report get a sample on https://www.axiommrc.com/request-for-sample/hc1982-lateral-flow-assay-market-report

LATERAL FLOW ASSAY MARKET OUTLOOK

The Lateral Flow Assay Market is mainly driven by the five major factors including high prevalence of infectious diseases across the globe coupled with the rapidly rising geriatric population, increasing demand for point-of-care testing, growing usage of home-based lateral flow assay devices and low production cost.  As indicated by United Nation estimate the global population aged 60 years was recorded 962 million in 2017 and is expected to double by 2050, to reach nearly 2.1 billion. Geriatric populace is prone to different chronic illnesses attributable to structural changes in the ageing population, which in turn is anticipated to support the growth of the lateral flow assay market.

Other factors such as technological advancements, growing awareness and growing product acceptance are likely to propel the global lateral flow assay market. However, lateral flow assay tests are only suitable for primary screening of point-of-care. The factors such as stringent regulation and inconsistency in test results are anticipated to hinder the growth of the market.  Nevertheless, the evolving applications of lateral flow assays coupled with the rising demand for lateral flow assays in the food & beverage industry provides the opportunity for the expansion of the lateral flow assay market. 

LATERAL FLOW ASSAY MARKET SEGMENTAL OVERVIEW

The report analyses the Lateral Flow Assay Market on the product, technique, application, end user and geography.

LATERAL FLOW ASSAY MARKET BY PRODUCT

On the basis of product, the market is classified as Kits & Reagents, Digital/Mobile Readers and Benchtop Readers. The lateral flow assay kits segment held the major market share of the global lateral flow assay market.  This can be attributed to the factors such as rising popularity of flow cytometry kits and its growing applications within the pharmaceutical, healthcare and homecare fields couple with the increasing burden of chronic diseases, and rising use of lateral flow kits in home care.

LATERAL FLOW ASSAY MARKET BY APPLICATION

Based on application, the market is segmented into clinical/point-of-care testing, veterinary diagnostics, food safety & environmental testing, and drug development & quality control testing. The clinical/point-of-care testing segment is sub categorised into infectious disease testing, cardiac marker testing, pregnancy & fertility testing, cholesterol & lipid testing, drugs-of-abuse testing and others. The clinical/point-of-care testing segment accounted for the largest share of this market owing to the increasing global prevalence of infectious diseases, cardiovascular diseases and  the shift in focus from centralized laboratories to decentralized point-of-care testing coupled with growth in funding for research on infectious disease and chronic diseases diagnostics are some the factors driving segmental  growth of this market.

 LATERAL FLOW ASSAY MARKET BY TECHNIQUE

By technique the lateral flow assay market is categorised into Competitive Assay, Sandwich Assay and Multiplex Detection Assay.  The rising population base and prevalence of chronic and infectious diseases coupled with the growing pressure to reduce healthcare costs, and rising demand for patient-centric care are the factors attributed to the growth of the market.

LATERAL FLOW ASSAY MARKET BY END USER

Considering the end-user segment, the market is segmented into Home Care, Diagnostic Laboratories, Hospitals & Clinics and Pharmaceutical & Biotechnology Companies and others. the hospitals and clinics segment accounted for the largest share of the market. This is primarily be attributed to the large number of diagnostic tests conducted in hospitals due availability innovative technologies and devices, growing patient inclination toward fast and early diagnosis and increasing adoption of point-of-care testing.

LATERAL FLOW ASSAY MARKET BY GEOGRAPHY

North America accounted for the largest share of the lateral flow assay market in 2018 followed by Europe and Asia Pacific. The dominance of the North America region is attributed to the generous investments and funding available for research in this field existing well-established healthcare system, rising geriatric population, increasing incidence of chronic diseases, quick adoption of new innovative products and the presence of the key players in this region.  Further, the growing aging population and growth in demands for intensive research in chronic diseases such as cancer, neurodegeneration, and cardiac diseases are the factors that favoured the market growth in the Europe region.  Moreover, Asia-Pacific region is observing robust growth in the market owing to the presence of developing nations such as China and India this will give rise to the Lateral Flow Assay Market growth.

LATERAL FLOW ASSAY MARKET KEY PLAYERS

The competitive market of lateral flow assay market appears fragmented owing to the many large and small players along with the new entrants churning the competition. The key players in the Lateral Flow Assay Market are The prominent players in the global lateral flow assay market are Abbott Laboratories, F. Hoffmann-La Roche AG Siemens AG, Becton and Dickinson Company, bioMérieux SA,Bio-Rad Laboratories, Inc., , Danaher Corporation, Thermo Fisher Scientific IncPerkinElmer, Inc., Hologic, Inc., Merck Millipore, ., QIAGEN N.V., Quidel Corporaton, Abcam plc., DCN Diagnostics, Surmodics, Inc., BioPorto Diagnostics A/S , Chembio Diagnostic Systems, Inc., Polysciences, Inc., Innova Biosciences Ltd., Microcoat Biotechnologie GmbH, and  Senova GmbH, Scienion AG  among others.

Buy now Lateral Flow Assay Market Report https://www.axiommrc.com/buy_now/hc1982-lateral-flow-assay-market-report

About Us:

Axiom Market Research & Consulting™ is a full-service market research and data analytics company providing key market intelligence to global companies to take informed business decisions pertaining to their marketing strategy, investments, new product launches, market competition, consumer or end users, social media trends etc. 

Axiom Market Research & Consulting™ offers market research services such as syndicated market research, custom market research, business consulting, and consumer/end user surveys. Under Business to Consumer (B2C) market research offerings, Axiom MRC assists its clients in finding quantitative information/preferences of its brands and services such as, awareness, usages, satisfaction, tracking, ethnicity etc. Axiom MRC offers data collection services through online surveys, social media, data processing and interpretation.

Axiom MRC with its experienced team of research and data analysts, has delivered more than 5000+ Market Research Projects, 3800+ Data Analytics Projects, 1200+ Business Support Projects and has a 800+ Global Client Base. Axiom Market Research & Consulting™ aims to become the preferred market research and data analytics company by providing key market intelligence solutions for client’s business growth.

Contact Us:

Axiom Market Research & Consulting™

3 Germay Dr. Ste 4 - 4666

Wilmington DE 19804

U.S.:- + 1 (845) 875-9786

U.K.:- + 44 (0) 20 3286 9707

Email: sales@axiommrc.com

Website: https://www.axiommrc.com/

Blog: https://industrywatch24.com/

Follow On

LinkedIn: https://www.linkedin.com/company/axiom-market-research-and-consulting/

Twitter:  https://twitter.com/AxiommrcCom

[researchvishal]

Radiopharmaceuticals Market To Undertake Strapping Growth By The End 2032 | FMI

The global radiopharmaceuticals market stands at US$ 6.2 Bn as of now and is expected to reach US$ 9.5 Bn by the year 2032 at a CAGR of 4.3% between 2022 and 2032.

Radiopharmaceuticals imply medications containing radioisotopes that could be used as both – therapeutic agents and diagnosis medications. Radiopharmaceuticals manage critical as well as chronic diseases. These days, various diagnostics are aimed towards organs with nuclear medicine radiopharmaceuticals.

PET and SPECT techniques are used in abundance while deploying radiopharmaceuticals. Some of the distinct features of radiopharmaceuticals include non-invasiveness, cost-effectiveness, easy of diagnosis, and higher sensitivity. Clinical applications include cardiology, oncology, lymphoma, and tumor.

Growing awareness regarding positive results provided by radiopharmaceuticals in checking chronic illness is one of the catalysts to radiopharmaceuticals market.

On the other hand, the fact that radiopharmaceuticals have half-life could restrain the market. It’s a known fact that radiopharmaceuticals involve higher investment. Short expectancy or half-life is one of the crucial factors restricting demand for radiopharmaceuticals. Thus, it’s only the developed regions who are able to increasingly adopt radiopharmaceuticals as of now. The developing economies still need to incorporate the technology to the fullest. Future Market Insights has walked through these functionalities with future prospects in its latest market study entitled ‘Radiopharmaceuticals Market’.

Key Takeaways from Radiopharmaceuticals Market

North America dominates the radiopharmaceuticals market due to rising frequency of cardiovascular diseases and cancer and the scenario is expected to persist even in the forecast period. Adopting innovative radioisotope production methods for treating chronic disorders is another reason.

Europe, led by the UK, is also expected to hold a significant market share due to the UK being subject to maximum incidences of cancer. Cancer Research UK estimate says that the UK alone houses 367,167 cancer patients.

The Asia-Pacific is poised to grow blatantly in the forecast period with it witnessing new product launches, collaborations, distribution agreements, acquisitions in an aplomb.

“The fact that radiopharmaceuticals are broadly used as biomarkers in molecular imaging is expected to take the radiopharmaceuticals market by storm in the upcoming period”, says an analyst from Future Market Insights.

Competitive Landscape

GE Healthcare inked an agreement with NorthStar Medical Radioisotopes, LLC for producing and distributing iodine-123 (I-123) capsules all across the US.

Bracco Diagnostics Inc., in March 2021, entered into partnership with CardioNavix, LLC for enhancing patients’ access to cardiac PET imaging. The new program is termed as ‘Bracco Mobile Isotope Service’, which ought to facilitate better patient care sites for providing cardiac PET imaging.

Jubilant Radiopharma, in August 2020, signed a MoU (Memorandum of Understanding) with Navidea Biopharmaceuticals, which focuses on an ELDA (Exclusive License and Distribution Agreement) for the latter’s diagnostic imaging agent called ‘Tilmanocept (technetium Tc 99m tilmanocept injection) in LATAM, Mexico, Canada, and the US.

Bayer AG, in June 2021, announced that it would acquire Noria Therapeutics Inc. along with PSMA Therapeutics Inc. with the objective of widening the former’s oncology portfolio that is into existence.

Norgine B.V., in March 2020, completed the acquisition of Azanta A/S, a specialty biopharmaceutical company. This included Nimorazole, a hypoxic radiosensitizer to treat cancer, and Angusta to facilitate labor induction.

Curium, in the year 2019, completed acquisition of MAP Medical, which would actually help it in strengthening the footprint all over the Europe with access to Baltic and Nordic countries.

The US FDA, in December 2020, completed approval of Gallium 68 PSMA-11 (Ga 68 PSMA-11). It holds the distinction of being the very first drug for PET imaging for diagnosing prostate cancer.

Top Radiopharmaceuticals companies : Siemens AG,Positron Corporation,Novartis (Advanced Accelerator Applications),Curium,GE Healthcare,Lantheus Holdings Inc.,Sotera Health LLC (Nordion Inc.),Bayer AG,Eckert & Ziegler,

Key Segments Covered in the Radiopharmaceuticals Industry Analysis

Radiopharmaceuticals Market by Radioisotope Type:

Technetium-99

Fluorine-18

Iodine-131

Leutetium-177

Yttrium-90

Gallium-68

Gallium-67

Rubidium-82

Iodine-123

Iodine-125

Indium-111

Others

Radiopharmaceuticals Market by Application:

Oncology

Cardiology

Gastroenterology

Neuroendocrinology

Neurology

Nephrology

Others

Radiopharmaceuticals Market by Source:

Cyclotrons

Nuclear Reactors

Radiopharmaceuticals Market by End User:

Hospitals

Diagnostic Imaging Centers

Ambulatory Surgical Centers

Cancer Research Institute

[neha24blog]

Cardiac Biomarkers Market To Reach $ 13.3 Billion By 2024: Grand View Research Inc.

Cardiac Biomarkers Market To Reach $ 13.3 Billion By 2024: Grand View Research Inc.

San Francisco, 24 Dec 2020: The Report Cardiac Biomarkers Market By Type (Troponin, Creatine kinase – MB (CK-MB), Natriuretic peptides – B-type Natriuretic Peptide (BNP) & N-terminal pro b-type Natriuretic peptide (NT-proBNP), Myoglobin, Ischemia Modified Albumin (IMA), Heart-type Fatty Acid Binding Protein (H-FABP), LDH isoenzymes), By Application (Acute Coronary Syndrome, Myocardial infarction,…

[ketshubhra]

Cardiac Biomarkers Market – 2025 | Supply Chain Analysis, Demand, Opportunity | COVID-19 Impact on Industry

According to Market Research Future (MRFR) Analysis – Cardiac Biomarkers Market is growing at a CAGR of 16.36% during the forecast period 2019 To 2025. The global industry segmented on the basis of type, location of testing, application, and region.

Cardiac Biomarkers Market -Overview

The rising focus on diagnosis is estimated to shape the cardiac biomarkers market in 2020 positively. The healthcare reports are made by Market Research Future, which includes market options for progress. An earning level of USD 4,236.02 Million is forecasted at a CAGR of 16.36% by 2025.

The effect of unhealthy lifestyles has contributed to the surge in cardiovascular illnesses, and this is predicted to transform the cardiac biomarkers market share in the coming period. Moreover, the intensifying emphasis on creating a viable treatment for cardiac problems is estimated to bolster the cardiac biomarkers market.

Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/8594

Cardiac Biomarkers Market Segmental Analysis 

The segmental study of the cardiac biomarkers market has been segmented based on type, region, location of testing, and application. On the basis of type, the cardiac biomarkers market has been divided into myoglobin, troponins (T and I), brain natriuretic peptide (BNP), myocardial muscle creatine kinase (CK-MB), or NT-proBNP and ischemia modified albumin (IMA). On the basis of the location of testing, the cardiac biomarkers market is segmented into laboratory testing and point of care testing. The application-based segmentation of the cardiac biomarkers market has been segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. Based on the region, the cardiac biomarkers market has been segmented into Africa, Europe, the Americas, Asia Pacific, and the Middle East.

Cardiac Biomarkers Market Regional Analysis 

The regional investigation of the cardiac biomarkers market includes regions such as Africa, Europe, the Americas, Asia Pacific, and the Middle East. The Americas regional markets are anticipated to be the principal market due to the extraordinary expenditure by the pharmaceutical industry. The Americas cardiac biomarkers are estimated to further show potential development to the upswing in investments made in the sector. The European cardiac biomarkers market is estimated to show a stable pace of growth and will develop with a rise in interest towards a study on the subject. The cardiac biomarkers market in the region of Asia Pacific is being led by the national markets in India, South Korea, Japan, China, and Australia. Owing to the mounting affordability for unconventional cardiac treatments and collective disposable incomes, the cardiac biomarkers market in the Asia Pacific is anticipated to be the fastest increasing regional market. The cardiac biomarkers market in the MEA region is predicted to display subdued development in the duration of the forecast period.

Cardiac Biomarkers Market Competitive Analysis

The competition in the market, though pronounced, is estimated to create a conducive outlook for the market. The investments in the market are also estimated to gain traction at a steady pace in the foreseeable future. The dynamic elements in the market are estimated to contribute to the development process extensively. The long-term development in the market is estimated to follow the pattern of a staggered pace rather than a continuous development plan. The companies in the market are observed as being more cautious in their long-term forecasting while accounting for unprecedented factors. The demand curves and growth pace are not estimated to pick up immediately and will require the presence of several key factors that can boost the sentiment in the global market. The reinforcement in the delivery chains is likely to enforce an optimistic effect on the market. Government backing is estimated to have a more important role in building the economy, and this is estimated to be extended to the development of this market as well.

The eminent contenders in the cardiac biomarkers market are ACS Biomarker (The Netherlands), Siemens AG (Germany), BD (Becton, Dickinson, and Company) (US), bioMérieux SA (France), Danaher Corporation (US), F. Hoffmann-La Roche Ltd (Switzerland), Trivitron Healthcare Pvt. Ltd. (India), Abbott Laboratories (US), Johnson and Johnson (US), Quidel Corporation (US), Randox Laboratories Limited (UK), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), and Novartis (Switzerland).

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/cardiac-biomarkers-market-8594

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com

NOTE: Our team of researchers are studying Covid-19 and its impact on various industry verticals and wherever required we will be considering covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

[sophiareddy123]

The Biomarkers Market is Segmented by Disease (Cancer, Cardiovascular Disorders, Neurological Disorders, Immunological Disorders, Renal Disorders, and Other Diseases), Type (Efficacy Biomarker, Safety Biomarker, and Validation Biomarker), Mechanism (Genetic, Epigenetic, Proteomic, Lipidomic, and Other Mechanisms), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America).

Download Free Sample Report - Biomarkers Market

[sapanas]

Cardiac Biomarkers Market 2020 Key Growth Drivers, Challenges, Demand, Upcoming Trends, Share, Revenue And Global Forecast To 2025

Cardiac Biomarkers Market Key Players

Key companies operating in the global cardiac biomarkers market are Abbott Laboratories, ACS Biomarker (The Netherlands), BD (Becton, Dickinson, and Company) (US), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (US), Danaher Corporation (US), Hoffmann-La Roche Ltd (Switzerland), Johnson and Johnson (US), Quidel Corporation (US), Randox Laboratories Limited (UK), Siemens AG (Germany), Thermo Fisher Scientific, Inc. (the US), Trivitron Healthcare Pvt. Ltd. (India), and Novartis (Switzerland).

Cardiac Biomarkers Market Overview

Cardiac biomarkers are often referred to as cardiac markers. The cardiac biomarkers (endogens, including enzymes, hormones, and proteins) are released into the blood if the heart is damaged or stressed. Generally, they are used to treat heart attack and acute coronary syndrome (ACS) or disorders associated with insufficient blood flow to the core

According to Market Research Future (MRFR), Cardiac Biomarkers Market is expected to cross USD 4236.02 Million 2025 at a CAGR of 16.36% by 2025 (forecast period). The research report serves as insight and knowledge repository for all market aspects including, regional markets, technology, types, and applications.

Cardiac Biomarkers Market Dynamics

There are a variety of factors that affect the development of the demand for cardiac biomarkers. Some of the main factors include growing demand for the diagnosis and testing of various cardiovascular diseases, the production and advancement of cardiac biomarkers and the growth of the patient population suffering from cardiovascular disease. Other primary growth factors include a rise in the number of new cardiovascular cases diagnosed per year and an increase in demand for disease-specific care in which cardiac biomarkers are used. Increased prevalence of the cardiovascular disease is projected to fuel the demand for cardiac biomarkers during the forecast period. Approximately 17.7 million people die each year from cardiovascular diseases (CVDs), according to the World Health Organization, and it is estimated to be the cause of 31% of the total deaths worldwide. About 80% of all deaths from CVDs are attributed to heart attacks and strokes. Nonetheless, the demand for cardiac biomarkers is experiencing constraints due to the emergence of other methods for cardiovascular disease diagnosis, along with high procedural costs, lack of full proof assurance, and strong competition among existing players.

Cardiac Biomarkers Market Segmentation

The global cardiac biomarkers market can be classified based on type, location of testing, application, and region.

Based on type, the cardiac biomarkers market can be segmented into Myocardial muscle Creatine Kinase (CK-MB), troponins (T and I), myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, ischemia-modified albumin (IMA), and others. Owing to its prodigious sensitivity and ability to reliably diagnose the heart events of an acute coronary syndrome (ACS), Troponins I and T are the leading revenue-generating segment in the global cardiac biomarkers market.

The location of testing is further segmented into point of care testing and laboratory testing. The point of care testing is projected to see steady growth in the forecast period due to its increasing popularity. The laboratory testing segment dominated the global market for cardiac biomarkers. Increased demand for cardiovascular disease diagnostics is increasing the revenue of this segment.

In terms of application, the demand for cardiac biomarkers can be divided in terms of diagnosis into congestive heart failure, myocardial infarction, acute coronary syndrome, atherosclerosis, and others.

Regionally, the cardiac biomarkers market can be classified into five regional markets, such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe dominate the global market for cardiac biomarkers due to an increasing population of patients suffering from cardiovascular disease (angina pectoris, myocardial infringement, etc.), lack of physical activity, and poor diet. Europe has one of the best healthcare services in the world, and the increasing participation of market players is boosting the European market for cardiac biomarkers. For example, in October 2019, Novartis received FDA approval for Entresto for the treatment of symptomatic heart failure in pediatric patients aged one year and older.

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/cardiac-biomarkers-market-8594

The Middle East and Africa have mainly been divided into two regions: The Middle East and Africa. The presence of favourable government initiatives and recent health reforms and the development of healthcare infrastructure in the Middle East is expected to increase market growth over the forecast period. Moreover, India, Southeast Asia, and China are evolving markets for cardiac biomarkers due to an increased incidence of coronary artery disease in these regions. Initiatives by the Government of Asia-Pacific towards the development of health care infrastructure are also expected to boost the growth of the market for cardiac biomarkers in the region.